

FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3A




FIGURE 3B




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B




FIGURE 6A




FIGURE 6B




FIGURE 7A




FIGURE 7B




FIGURE 8A




FIGURE 8B




FIGURE 9

**Weight of Human Colon Adenocarcinoma (HT-29) in CD-1
Nude Mice Treated with Combination Therapy**




FIGURE 10




FIGURE 11

Growth of Human Colon Adenocarcinoma (HT-29) in CD-1 Nude Mice




FIGURE 12




FIGURE 13




FIGURE 14


Weight of Human Prostate Carcinoma (PC-3)
in SCID Mice

FIGURE 15

Weight of Human Prostate Carcinoma(DU145)
in SCID Mice





FIGURE 16





FIGURE 17

Weight of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice



Growth of Human Breast Adenocarcinoma (MDA-MB-231) in CD-1 Nude Mice




FIGURE 18





FIGURE 19



B Weight of Human Pancreatic Carcinoma (BxPC-3) in CD-1 Nude Mice




FIGURE 20





FIGURE 21

**Weight of Human Cisplatin-Resistant Breast Adenocarcinoma
Implanted at the Fat Pad of SCID Mice**




Statistical Analysis:	P value
Saline : Cisplatin	0.0834
Saline : Taxol	<0.0001
Saline : SEQ ID NO:1	<0.0001
SEQ ID NO:1 : Cisplatin	0.0007
SEQ ID NO:1 : Taxol	0.9547


FIGURE 22

Growth Of Human Breast Cancer (MDA-CDDP-S4) In CB-17-SCID Mice Treated With Taxol, SEQ ID NO:1, and Taxol+ SEQ ID NO:1 (Orthotopical transplant)

A



B



SEQ ID NO:1: Taxol $P = 0.0133$
 SEQ ID NO:1: SEQ ID NO:1+Taxol $P = 0.0003$
 Taxol: SEQ ID NO:1+Taxol $P < 0.0001$

C





FIGURE 23

Weight of Human Taxol-Resistant Breast Adenocarcinoma
(MDA-MB435-To.1) Implanted at the Fat Pad of SCID Mice

A



B





FIGURE 24

**Growth of Human Breast Adenocarcinoma (MDA-MB435-To. 1)
in SCID Mice**

A

**Weight of Human Breast Adenocarcinoma (MDA-MB-435-To. 1)
in SCID Mice**

B





FIGURE 25

A

**Growth of Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**

B



**Weight of Human Promyelocytic Leukemia HL-60
(Taxol-Resistant) in SCID Mice**


FIGURE 26

**Growth of Human Multi-Drug Resistance Colon
Adenocarcinoma (LS513) in SCID Mice**

A



B



**Weight of Human Colon Multi-Drug Resistance Carcinoma (LS513)
in SCID Mice**

C




FIGURE 27

>gi|4557844|ref|NM_001034.1| Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA

CCCAGGCGCAGCCAATGGGAAGGGTCGGAGGCATGGCAGCCAATGGGAAGGGCCGGGGCACCAAAGCC
AATGGGAAGGGCCGGGAGCGCGCGCGCGGGAGATTAAAGGCTGCTGGAGTGAGGGGTCGCCCCGTGCAC
CCTGTCCAGCCGTCCTGTCTGGCTGCTCGCTCTGCTCGCTCCACTATGCTCTCCCTCCGTG
TCCCCTCGCGCCCATCACGGACCCGAGCAGCTGCAGCTCTCGCCGCTGAAGGGGCTCAGCTTGGTCGA
CAAGGAGAACACGCCGCCGGCCCTGAGCGGACCCGCGTCTGGCCAGCAAGACCGCGAGGAGGATCTTC
CAGGAGCCACGGAGCCGAAACTAAAGCAGCTGCCCCCGGCTGGAGGATGAGCCGCTGCTGAGAGAAA
ACCCCGCGCGCTTTGTTCATCTTCCCATCGAGTACCATGATATCTGGCAGATGTATAAGAAGGCAGAGGC
TTCCCTTTTGGACCGCGAGGAGGTTGACCTCTCCAAGGACATTCAGCACTGGGAATCCCTGAAACCCGAG
GAGAGATATTTATATCCCATGTTCTGGCTTTCTTTCAGCAAGCGATGGCATAGTAAATGAAACTTGG
TGGAGCGATTTAGCCAAAGATTACAGATTACAGAAGCCCGCTGTTTCTATGGCTTCCAAATTGCCATGGA
AAACATACATTCTGAAATGTATAGTCTTCTTATGACACTTACATAAAAGATCCCAAAGAAAGGGAAATTT
CTCTTCAATGCCATTGAAACGATGCCCTTGTGTCAAGAAGAAGGCAGACTGGGCGCTTGGCTGGATTGGGG
ACAAAGAGGCTACCTATGGTGAACGTGTTGTAGCTTTGCTGCAGTGGGAAGGCATTTCTTTTCCGGTTC
TTTTGCGTCGATATTCTGGCTCAAGAAACGAGGACTGATGCCCTGGCCTCACATTTTCTAATGAACATTAT
AGCAGAGATGAGGGTTTACACTGTGATTTTGGCTTGCCTGATGTTCAAACACCTGGTACACAAACCATCGG
AGGAGAGAGTAAGAGAAATAATTATCAATGCTGTTTCGGATAGAACAGGAGTTCTCTCACTGAGGCCCTTCCC
TGTGAAGCTCATTGGGATGAATTGCACCTTAATGAAGCAATACATTGAGTTTGTGGCAGACAGACTTATG
CTGGAACTGGGTTTTAGCAAGGTTTTTCAAGTAGAGAACCATTGACTTTATGGAGAATATTTCACTGG
AAGGAAAGACTAATCTTTGAGAAGAGAGTAGGCGAGTATCAGAGGATGGGAGTGATGTCAAGTCCAAC
AGAGAATTTCTTTTACCTTGGATGCTGACTTCTAAATGAAGTGAAGATGTGCCCTTACTTGGCTGATTTTT
TTTTTCCATCTCATAAGAAAAATCAGCTGAAGTGTACCAACTAGCCACACCATGAATTGTCCGTAATGT
TCATTAAACAGCATCTTTAAAACTGTGTAGCTACCTCACACCAGTCTGTCTGTTTATAGTGCTGGTAGT
ATCACCTTTTGGCAGAAAGCCCTGGCTGGCTGTGACTTACCATAGCAGTGACAATGGCAGTCTTGGCTTTA
AAGTGAGGGGTGACCCCTTTAGTGAGCTTAGCACAGCGGGATTAAACAGTCTTTAACCAGCACAGCCAGT
TAAAAGATGCAGCCTCACTGCTTCAACGCAGATTTTAATGTTTACTTAAATATAAACCTGGCACCTTACA
AACAAATAACATTGTTTTGTACTCACGGCGCGGATAATAGCTTGATTATTTGGTTTCTACACCAAATA
CATTTCTCTGACCACATAATGGGAGCCAAATTCACAATTCACTAAGTGACTAAAGTAAGTTAACTTGTGTA
GACTAAGCATGTAATTTTTAAGTTTTATTTTAAATGAATTAATATTTGTTAACCACCTTTAAAGTCAGT
CCTGTGTATACCTAGATATTAGTCAGTTGGTGCCAGATAGAAGACAGGTTGTGTTTTATCCTGTGGCTT
GTGTAGTGTCTGGGATTCTCTGCCCCCTCTGAGTAGAGTGTGTGGGATAAAGGAATCTCTCAGGGCAA
GGAGCTTCTTAAGTTAAATCACTAGAAATTTAGGGGTGATCTGGGCTTCATATGTGTGAGAAGCCGTTT
CATTTTATTTCTCACTGTATTTTCTCAACGTCGGTTGATGAGAAAAATTTCTGAAGAGTTTTCATAT
GTGGGAGCTAAGGTAGTATTGTAAATTTCAAGTCATCCTTAAACAAAATGATCCACCTAAGATCTTGCC
CCTGTTAAGTGGTGAATCAACTAGAGGTGGTTCTTACAAGTTGTTTCACTCTAGTTTGTGTTGGTGTAAAG
TAGGTTGTGTGAGTTAATTCATTTATATTACTATGCTGTGTTAAATCAGAAATTTTTTATTATCTATGTT
CTTCTAGATTTTACCTGTAGTTCTATAAAAAAAAAAAAAAAAAAAAAA